Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
anemarsaponin B
Cat. No.:
0225LY-1159
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Anemarsaponin B demonstrates anti-inflammatory properties by suppressing NF-κB transcriptional activity, likely via the p38 MAP kinase pathway, and has the capacity to inhibit PAF-induced platelet aggregation.
Synonym:
139051-27-7; Timosaponin B III; Anemarsaponin BIII; (2R,3R,4S,5S,6R)-2-[(2S)-4-[(1R,2S,4S,8S,9S,12S,13S,16S,18R)-16-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-6-en-6-yl]-2-methylbutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
CAS No.:
139051-27-7
Compound CID:
44575944
Formula:
C45H74O18
Formula Weight:
903.06
Specification
Relative Density:
1.43 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Anemarsaponin B can be used in pharmacological studies to examine its anti-diabetic and anti-inflammatory activities.
Library Information
Target:
p38 MAPK; NF-κB; MEK; COX; NO synthase
Receptor:
COX; MEK; NF-κB; NO synthase; p38
Pathways:
Immunology/Inflammation; Neuronal signaling; NF-κB; MAPK
Plate Number:
AOCL-15
Plate Location:
h6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
27.5 mg/mL; 30.45 mM
